Crossmark

Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma

Published Online: 2021-09-20

Published Print: 2022-05

Authors

Panaampon, Jutatip

Kariya, Ryusho

Okada, Seiji https://orcid.org/0000-0003-3124-5206
Funding

Funding for this research was provided by:

Japan Agency for Medical Research and Development (18fk0410008h003)

Japan Society for the Promotion of Science (16K08742)
License Information

Text and Data Mining valid from 2021-09-20

Version of Record valid from 2021-09-20
More Information

Article History

Received: 8 March 2021

Accepted: 6 September 2021

First Online: 20 September 2021

Declarations

:

: The authors declare that they have no conflict of interest.

: Mice were bred and cared for in the animal research facility according to institutional guidelines. All experimental procedures in this study were approved by the Institutional Animal Care and Use Committee at Kumamoto University, Japan.

Document is current